Johnson & Johnson (JNJ)

US — Healthcare Sector

Peers: ABBV NVS NVO MRK AZN UNH PFE AMGN SNY GILD

Automate Your Wheel Strategy on JNJ

With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

$10,000 to Invest? Coca-Cola or Johnson & Johnson- One Stock Is More Reliable

JNJ, KO
Published: April 06, 2026 by: 24/7 Wall Street
Sentiment: Positive

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and Coca-Cola (NYSE:KO) both closed out 2025 with Q4 earnings and have raised dividends for 63 consecutive years.

image for news $10,000 to Invest? Coca-Cola or Johnson & Johnson- One Stock Is More Reliable

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

JNJ
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

image for news Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Here's Why You Don't Bet Against This Dividend King

JNJ
Published: March 31, 2026 by: 24/7 Wall Street
Sentiment: Neutral

Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner.

image for news Here's Why You Don't Bet Against This Dividend King

This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

JNJ
Published: March 30, 2026 by: Zacks Investment Research
Sentiment: Positive

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

image for news This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock

5 Defensive Stocks to Buy Amid Market's Recent Bloodbath

DUK, ETR, JNJ, KO, STZ
Published: March 30, 2026 by: Zacks Investment Research
Sentiment: Positive

DUK, ETR, STZ, KO and JNJ emerge as defensive picks as market volatility spikes, offering stability through dividends, low beta, and steady growth strategies.

image for news 5 Defensive Stocks to Buy Amid Market's Recent Bloodbath

Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?

JNJ
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive

JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.

image for news Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?

J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

JNJ
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Positive

JNJ stock holds strong above key SMAs for 8 months as Innovative Medicine strength, new drugs and MedTech gains fuel momentum despite patent and legal risks.

image for news J&J Stock Trading Above 200- & 50-Day SMA for 8 Months: Time to Buy?

Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet

JNJ
Published: March 24, 2026 by: Zacks Investment Research
Sentiment: Neutral

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

image for news Brokers Suggest Investing in Johnson & Johnson (JNJ): Read This Before Placing a Bet

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

A, JNJ
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Positive

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

image for news These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

J&J Expands New Drug Portfolio With Icotyde's FDA Approval

JNJ
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Positive

J&J wins FDA nod for Icotyde, a once-daily oral psoriasis pill, boosting its new drugs portfolio and challenging injectable treatments in a key market.

image for news J&J Expands New Drug Portfolio With Icotyde's FDA Approval

The Big 3: ORCL, JNJ, SBUX

JNJ, ORCL, SBUX
Published: March 19, 2026 by: Schwab Network
Sentiment: Neutral

Dan Deming urges investors to stay nimble as markets grapple with crude oil, gold, and silver volatility. That said, he sees trading opportunities available in the markets.

image for news The Big 3: ORCL, JNJ, SBUX

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

JNJ
Published: March 19, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

image for news Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

JNJ
Published: March 19, 2026 by: Forbes
Sentiment: Neutral

Question: What caused JNJ stock to rise 70% since early 2025?

image for news JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

TrumpRx lists many medicines at prices higher than paid in UK

ABBV, AMGN, AZN, BMY, GILD, GSK, JNJ, LLY, MKGAF, MKKGY, NVO, NVS, PFE, RHHBY, SNY, TAK, VRTX
Published: March 18, 2026 by: Reuters
Sentiment: Negative

U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.

image for news TrumpRx lists many medicines at prices higher than paid in UK

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

JNJ
Published: March 18, 2026 by: CNBC
Sentiment: Positive

Johnson & Johnson said the FDA has approved its once-daily psoriasis pill Icotyde. Icotyde targets IL-23, rivaling best-selling shots Tremfya and Skyrizi.

image for news FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

J&J or Merck? Key Factors Investors Must Weigh Right Now

JNJ, MRK
Published: March 18, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.

image for news J&J or Merck? Key Factors Investors Must Weigh Right Now

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

JNJ
Published: March 05, 2026 by: PRNewsWire
Sentiment: Neutral

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens 83.3% of patients were alive at three years, indicating durable clinical benefit HORSHAM, Pa., March 5, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor …

$image for news Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026

JNJ, PEP, XOM
Published: March 04, 2026 by: 24/7 Wall Street
Sentiment: Positive

Volatility is again picking up, and it's a good idea to focus more on safety.

image for news Top 3 Dividend Aristocrat Stocks to Buy for Strong Returns in 2026

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

JNJ
Published: March 04, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

image for news Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

JNJ
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Wasatch Global Value Fund Q4 2025 Performance Review

BABA, C, JNJ, SSNLF, T, VICI
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive

Production volumes for Samsung's foundry business have been boosted by demand for HBM chips. Johnson & Johnson announced plans to spin its orthopedics business (joint replacements, surgical tools, etc.) out of its med tech division in order to focus more tightly on higher-growth areas such as oncology. While VICI's most recent earnings results were modestly positive, a meaningful softening in casino revenues weighed on the stock in the quarter.

image for news Wasatch Global Value Fund Q4 2025 Performance Review

Retire Comfortably With These Dividend Growth Stocks

GS, JNJ, KO, LOW
Published: March 03, 2026 by: 24/7 Wall Street
Sentiment: Neutral

Of all the retirement activities you can engage in, worrying about your financial security shouldn't be one of them.

image for news Retire Comfortably With These Dividend Growth Stocks

Immunology, Neuroscience Step Up as Key Growth Engines for J&J

JNJ
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Neutral

JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.

image for news Immunology, Neuroscience Step Up as Key Growth Engines for J&J

4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam

BAYRY, JNJ, LLY, SNY
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive

In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.

image for news 4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam

Best Dividend Aristocrats For March 2026

ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CHD, CHRW, CINF, CL, CLX, CTAS, DOV, ECL, ED, EMR, BF-A, BF-B, ERIE, ES, EXPD, FAST, FDS, FRT, GD, GPC, GWW, HRL, IBM, ITW, JNJ, KMB, KO, KVUE, LIN, LOW, MCD, MDT, MKC, NDSN, NEE, NOBL, NUE, O, PEP, PG, PNR, PPG, ROP, SHW, SJM, SPGI, SPY, SWK, SYY, TGT, TROW, WMT, WST, XOM
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.

image for news Best Dividend Aristocrats For March 2026

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?

JNJ
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson's JNJ stock has risen 38.4% in the past six months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) for more than eight months since mid-June 2025 due to its positive earnings outlook and improving fundamentals.

image for news J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

JNJ
Published: February 26, 2026 by: PRNewsWire
Sentiment: Neutral

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role of immunotherapy in prostate cancer RARITAN, N.J., Feb. 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced preliminary results from a Phase 1b study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific T-cell engaging antibody, in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.

image for news Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Are You Looking for a High-Growth Dividend Stock?

JNJ
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

image for news Are You Looking for a High-Growth Dividend Stock?

Can J&J Sustain Its Double-Digit Oncology Growth Streak?

JNJ
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive

Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the foundational gold standard treatment.

image for news Can J&J Sustain Its Double-Digit Oncology Growth Streak?

Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?

JNJ
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

1 (current)
2
3

About Johnson & Johnson (JNJ)

IPO Date 1943-01-02
Website https://www.jnj.com
Industry Drug Manufacturers - General
CEO Joaquin Duato
Employees 138100

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.